Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer

标题
Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
作者
关键词
Flubendazole, Castration-resistant prostate cancer (CRPC), P53, Ferroptosis, Anti-tumor
出版物
PHARMACOLOGICAL RESEARCH
Volume 164, Issue -, Pages 105305
出版商
Elsevier BV
发表日期
2020-11-14
DOI
10.1016/j.phrs.2020.105305

向作者/读者发起求助以获取更多资源

Reprint

联系作者

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search